1.5 Pharmacology, Toxicology, and Pharmaceutics  4.1 Medicine 

THE SCIENTIFIC DISCUSSION OF KEY ISSUE ASPECTS OF MITOCHONDRIAL DYSFUNCTION AND PHARMACOTHERAPEUTIC MANAGEMENT STRATEGIES IN PARKINSON'S DISEASE: FOCUS ON MITOPHAGY AND NAD+ METABOLISM

Mitochondrial dysfunction Parkinson’s disease therapeutic strategies mitochondrial medicine

Authors

August 4, 2025

Downloads

Parkinson's disease (PD) is a prevalent neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons and the accumulation of α-synuclein in Lewy bodies. Mitochondrial dysfunction plays a central role in both sporadic and familial PD, contributing to bioenergetic deficits, oxidative stress, and mitochondrial DNA (mtDNA) damage. This review examines the pivotal role of mitophagy—the selective autophagy of damaged mitochondria—in maintaining mitochondrial integrity and explores therapeutic strategies aimed at restoring mitochondrial function. Additionally, we discuss the significance of Nicotinamide adenine dinucleotide (NAD+) metabolism in mitigating mitochondrial dysfunction and its implications for PD pathogenesis. Emerging pharmacological interventions targeting mitophagy and NAD+ metabolism are proposed as promising therapeutic avenues to slow or halt neurodegeneration in PD. Mitochondrial dysfunction plays a central role in the pathogenesis of Parkinson’s disease (PD), contributing to neuronal degeneration through oxidative stress, bioenergetic failure, and impaired quality control mechanisms. This review critically examines key aspects of mitochondrial dysfunction in PD, with a focus on mitophagy and NAD+ metabolism as pivotal therapeutic targets. Dysregulated mitophagy, particularly involving PINK1-Parkin signaling, leads to the accumulation of damaged mitochondria, exacerbating neurodegeneration. Additionally, declining NAD+ levels impair mitochondrial bioenergetics and cellular resilience, further aggravating PD progression. Emerging therapeutic strategies, including NAD+ supplementation, mitophagy enhancers, and metabolic modulators, hold promise for restoring mitochondrial homeostasis and neuroprotection. By integrating current research, this discussion highlights the potential of targeting mitochondrial pathways to develop novel interventions for PD, while addressing remaining challenges in translational application.

 

Most read articles by the same author(s)

1 2 > >> 

Similar Articles

1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.